Let the inventions grow!

About us

From lab to market

We are here to help inventions grow. We are your new team member, who can help you make the journey from groundbreaking invention to market-storming product.

We are i&i Prague, a biotech hub located right in the centre of Europe, and our objective is to identify the potential of, and nurture, new inventions in MedTech, Biotech, Diagnostics and Drug Discovery by Central European scientists and researchers. We do this by sourcing or, in some cases, providing financial investment for your invention, then we will help you with product development and, ultimately, market entry.

Our background

We operate as a private company under the wings of the Czech Academy of Sciences and its Institute of Organic Chemistry and Biochemistry (IOCB). From 1994 to 2002, the IOCB was led by Dr. Antonín Holý, whose team  (Truvada, Atripla, Complera, Eviplera), invented and developed hugely effective and successful anti-HIV drugs. We believe that this is a legacy to build upon and that, with yours and our combined expertise, we can make this world a better place and help millions of people.

      

 

Read more

About us

Investment process

1

Submit your project

Submit your invention to i&i Prague for evaluation. i&i Prague team will contact you within a week for further discussion of your project.

Start now

2

Project evaluation and investment

Selected projects will be subject to thorough evaluation including technical, marketing and business aspects. We will finalise a business plan in collaboration, and submit it to the i&i Prague Investment Board for approval.

3

Launching the project

Once approved, your project will be covered by an investment or collaborative agreement and will be run as either a spin-off company with defined co-ownership, or as a collaborative project with shared IP rights in defined ratio.

4

Project management

Each project will have an agreed action plan and a dedicated team led by a project manager. This team will be responsible for implementation and day-to-day management. Additionally, a nominated steering committee (or supervisory board) will be responsible for strategic decisions and dispute resolution.

5

Exit strategy

As the project progresses, the i&i Prague team will search for additional partners, licensees, customers or investors to ensure future development. Our strategy is to develop the project to be ready for acquisition or out-licensing, or to reach sufficient sales, within 3-5 years after signature of the agreement.

6

 Submit your project.

Fill in following form and we will get in touch.

Download

News

Novel partnership for iBodies has been facilitated by i&i Prague and IOCB Tech managers

20.10.2018

The Institute of Macromolecular Chemistry (IMC) in cooperation with the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague) started novel collaborative project with the International Cannabis and Cannabinoids Institute (ICCI). The project deals with a development of a novel synthetic antibody mimetics called iBodies® for clinical diagnostic.

Conference BIOTECHNOLOGY 2018

16.8.2018

The Biotechnology Conference is an international conference about biotechnologies as well as an opportunity for intersectoral cooperation and technology transfer. It will be held the 19th of September 2018 and…

Our portfolio